Upload
venice
View
37
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Isoflurane and Alzheimer’s Disease Neuropathogenesis. Zhongcong Xie, M.D., Ph.D. Genetics and Aging Research Unit MassGeneral Institute for Neurodegenerative Disease Department of Neurology Department of Anesthesia and Critical Care Massachusetts General Hospital Harvard Medical School - PowerPoint PPT Presentation
Citation preview
Zhongcong Xie, M.D., Ph.D.
Genetics and Aging Research Unit
MassGeneral Institute for Neurodegenerative Disease
Department of Neurology
Department of Anesthesia and Critical Care
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts
Isoflurane and Alzheimer’s Disease Neuropathogenesis
Isoflurane and Alzheimer’s Disease Neuropathogenesis
Alzheimer’s disease (AD) is one of the greatest public health problems in the US and in the world, and its impact will only increase with demographic changes anticipated in the coming decades.
Currently, AD affects 4.5 millions Americans. It it estimated that the number of AD patients will reach 13.2 millions in the US by 2050, if no treatments are found.
A production/accumulation is the important part of the AD neuropathogenesis.
Increasing evidence also suggests a role for caspase activation and apoptosis in AD neuropathogenesis.
An estimated 100 million patients worldwide have surgery each year. Several reports have suggested that anesthesia and surgery may facilitate the development of Alzheimer’s disease (AD).
(Reviewed in Xie and Tanzi, 2006)
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
(Xie et al., 2006a)
Isoflurane induces caspase-3 activation, reduces cell viability and increases A generation in H4 human
neuroglioma cells overexpressing APP (H4-APP cells)
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
(Xie et al., 2006b)
Isoflurane-induced caspase-3 activation in H4-APP cells is dose-dependent
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
(Xie et al., 2007)
Isoflurane induces caspase-3 activation without detectable changes in APP processing
and A generation in naïve H4 cells
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
(Xie et al., 2007)
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
Z-VAD attenuates the isoflurane effects on caspase-3 activation, APP processing and A levels
(Xie et al., 2007)
Isoflurane enhance levels of BACE and -secretase
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
(Xie et al., 2007)
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
iA5 and clioquinol attenuate the isoflurane-induced caspase-3 activation
(Xie et al., 2007)
A potentiates the isoflurane-induced caspase-3 activation
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
(Xie et al., 2007)
Summary
QuickTime™ and aTIFF (LZW) decompressor
are needed to see this picture.
Acute perioperative insults, e.g., hypoxia, hypocapnia and anesthetics, may affect A metabolism and apoptosis, thereby increasing the risk of developing AD.
Isoflurane induces a vicious cycle of apoptosis and A generation.
Isoflurane may induce apoptosis via A oligomerization/fibrillar aggregation.
Conclusion
Systematically assess the effects of isoflurane on apoptosis, APP processing, A generation, amyloid amount/disposition, regulation of gene expression in both mice and humans.
Further determine the molecular mechanisms by which isoflurane induces apoptosis, affects APP processing and increases A accumulation.
Future direction
Rudolph E. Tanzi, Ph.D.Yuanlin Dong, M.D., M.S.Uta MaedaRob Moir, Ph.D.Guohua Zhang, M.D., Ph.D.Bin Zhang, M.D.Genetics and Aging Research Unit, Department of Neurology,Department of Anesthesia and Critical CareMassachusetts General Hospital and Harvard Medical School****************************************************************************Deborah J. Culley, M.D.Gregory Crosby, M.D.Department of Anesthesia,Brigham & Women’s Hospital and Harvard Medical School****************************************************************************Weiming Xia, Ph.D.Center for Neurological Diseases, Harvard Institute of Medicine and Harvard Medical School**************************************************************************** NIH MH 60009-02 and AG 014713-07 to Rudy Tanzi. NIH K12 (AG 000294-17), K08 (NS048140-01), P60 (AG008812-15) and Jahnigen award from
American Geriatrics Society to Zhongcong Xie
Acknowledgements